Anatomy, Biology and Concepts, Pertaining to Lung Cancer Stage Classification
|
|
- Barnaby Holland
- 5 years ago
- Views:
Transcription
1 COMMENTARY Anatomy, Biology and Concepts, Pertaining to Lung Cancer Stage Classification Frank C. Detterbeck, MD,* Lynn T. Tanoue, MD,* and Daniel J. Boffa, MD* Abstract: The proposed lung cancer stage classification system remains grounded in anatomic characteristics, although the large patient database contributing to this revision has dramatically expanded our body of knowledge. Predictably this has led to increased complexity due to the identification of an increasing number of subpopulations of patients. Patterns of clinical presentation characterizing these subgroups may provide clues about the propensity of tumors within a subgroup toward a particular pattern of biologic behavior. This article explores concepts regarding tumor biology that can be applied to the anatomically based new staging system. Key Words: Lung cancer, Anatomy, Biology, Concepts, Stage. (J Thorac Oncol. 2009;4: ) A stage classification system provides a common nomenclature about patients with a particular type of cancer. A common language facilitates communication among different centers, allowing observations from different sources to be combined and thereby enhance our collective knowledge. As knowledge is gained, further details of a staging system can be defined, and thus the system requires periodic revision and refinement. In lung cancer, a major effort led by the International Association for the Study of Lung Cancer (IASLC) Staging Committee was undertaken to inform a revision of the Union Internationale Contre le Cancer and American Joint Committee on Cancer staging system, 1 5 involving an unprecedented extent of data collection and scientific analysis. 1 5 This has prompted us to reflect on the goals of a staging system, the limitations of our current understanding of the biology of lung cancer, and how underlying concepts can help or hinder our ability to make new observations. Inherent in the development of the nomenclature of a staging system is the ability to define homogeneous patient cohorts. This raises the question of how homogeneity is *Thoracic Oncology Program, Yale Cancer Center; Division of Thoracic Surgery Department of Surgery, Yale University; and Division of Pulmonary and Critical Care Medicine, Department of Medicine, Yale University, New Haven, Connecticut. Disclosure: The authors declare no conflicts of interest. Address for correspondence: Frank C. Detterbeck, MD, Division of Thoracic Surgery, Yale University School of Medicine, 330 Cedar St., BB 205, New Haven, CT frank.detterbeck@ yale.edu Copyright 2009 by the International Association for the Study of Lung Cancer ISSN: /09/ defined. While many measures can be considered, the one most commonly used is prognosis. Indeed, this is the primary end point used in the analysis and staging recommendations of the IASLC staging committee. 2,6,7 Another common expectation of a staging system is to define patient cohorts for which the same treatment approach is appropriate. However, it must be recognized that prognosis and treatment approaches are not static. There is an incessant quest to define treatments that lead to better outcomes. Moreover, prognosis is continually changing due to progress in aspects other than treatment. Advances in imaging affect the prognosis of stage groups through the resultant stage migration. 8,9 Changing methods of detection (e.g., computed tomography screening) also affect prognosis by altering the spectrum of disease that is encountered. 10 Therefore, grouping patients by prognosis alone carries the risk that some patients will be grouped together because they happen to have the same prognosis at the current time, even though they are inherently different. For example, within stage IIIa the IASLC staging revision groups together patients with N2 involvement, those with a T4N0M0 tumor and those with additional nodules of cancer in a different ipsilateral lobe. 2 As we explore new treatment approaches, we may find that the optimal treatment and resultant prognosis for subpopulations of patients within a stage group or even a T,N, and M descriptor group may be divergent. The ideal stage classification system would reflect the biology of the tumor, because patients grouped by tumor biologic characteristics will probably continue to share many similarities even as treatment approaches, staging procedures and outcomes change. This suggests that classification by molecular biologic characteristics may be more useful than by anatomic characteristics. However, our current ability to predict tumor biology is rudimentary, and we have a poor understanding of which biologic characteristics of a tumor are really the key factors There was no choice for the IASLC staging committee but to describe patient cohorts using anatomic characteristics. Nevertheless, as we look to the future we should use whatever means we currently have available to define biologic behavior. This article proposes a categorization of lung cancer by patterns of clinical presentation, which are postulated to reflect biologic behavior. This approach has the advantage that it can be used with the currently available anatomic descriptors as defined by the proposed IASLC stage classification system, which are summarized in Tables 1 and 2. Journal of Thoracic Oncology Volume 4, Number 4, April
2 Detterbeck et al. Journal of Thoracic Oncology Volume 4, Number 4, April 2009 TABLE 1. Definitions for T,N,M Descriptors in the IASLC Staging Classification a TNM Descriptions Subgroup b T (Primary Tumor) T0 No primary tumor T1 Tumor 3 cm c, surrounded by lung or visceral pleura, not more proximal than the lobar bronchus T1a Tumor 2 cm c T1a T1b Tumor 2 but 3 cm c T1b T2 Tumor 3 but 7 cm c or tumor with any of the following d : Invades visceral pleura, involves main bronchus 2 cm distal to the carina, atelectasis/obstructive pneumonia extending to hilum but not involving the entire lung T2a Tumor 3 but 5 cm c T2a T2b Tumor 5 but 7 cm c T2b T3 Tumor 7 cm c T3 7 or directly invading chest wall, diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium, T3 Inv or tumor in the main bronchus 2 cm distal to the carina e, T3 Centr or atelectasis/obstructive pneumonitis of entire lung, T3 Centr or separate tumor nodule(s) in the same lobe T3 Satell T4 Tumor of any size with invasion of: heart, great vessels, trachea e, recurrent laryngeal nerve, esophagus, T4 Inv vertebral body, or carina e ; or separate tumor nodule(s) in a different ipsilateral lobe T4 Ipsi Nod N (regional lymph nodes) N0 No regional node metastasis N1 Metastasis in ipsilateral peribronchial and/or perihilar lymph nodes and intrapulmonary nodes, including involvement by direct extension N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s) N3 Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene or supraclavicular lymph node(s) M (distant metastasis) M0 No distant metastasis M1a Separate tumor nodule(s) in a contralateral lobe; M1a Contr Nod or tumor with pleural nodules or malignant pleural dissemination f M1a Pl Dissem M1b Distant metastasis M1b Special situations: TX, NX, MX T, N, or M status not able to be assessed Tis Focus of in situ cancer Tis T1 e Superficial spreading tumor of any size but confined to the wall of the trachea or mainstem bronchus T1 SS a Reflects the IASLC staging Committee s recommendations and not necessarily the UICC 7th Edition Staging System. b These subgroup labels are not defined in the IASLC publications, but are added here to facilitate a clear discussion. Goldstraw et al., J Thorac Oncol 2007;2: ; Rami-Porta et al., J Thorac Oncol 2007;2: ; Postmus et al., J Thorac Oncol 2007;2: ; Rusch et al., J Thorac Oncol 2007;2: c In greatest dimension. d T2 tumors with these features are classified as T2a if 5 cm. e The uncommon superficial spreading tumor in central airways is classified as T1. f Pleural effusions are excluded that are cytologically negative, nonbloody, transdative, and clinically judged not to be due to cancer. IASLC, International Association for the Study of Lung Cancer; TNM, tumor, node, metastasis. Proposed Categories of Biologic Behavior Because our understanding is limited, an attempt at characterization of tumors according to biologic behavior is inherently speculative. We postulate that there are four types of biologic behavior: tumors with a primary propensity for direct local invasion, those with a propensity for spread to regional lymph nodes, those with a propensity to develop additional foci of cancer within the lung(s), and those with a propensity for systemic dissemination (Table 3). These categories fit commonly observed patterns of clinical presentation, e.g., patients presenting with large tumors and no metastases, others with small tumors and metastatic deposits in nodes and/or distant sites, and patients with multiple foci of cancer within the lung parenchyma in the absence of any extrapulmonary involvement. In Table 4 the new IASLC stage groups and tumor, node, metastasis descriptors are depicted aligned according to these clinical patterns. Categorization according to patterns of clinical presentation may be an important concept that allows us to recognize differences among patients within a stage grouping and similarities among patients in different groups. In Table 4, the patterns of presentation (and the presumed patterns of biologic behavior) are aligned vertically, while the stage groupings are aligned horizontally. This underscores that some stage groups combine patients with very different clinical presentations, and that there are similarities between subgroups of patients that belong to different stage groups. 438 Copyright 2009 by the International Association for the Study of Lung Cancer
3 Journal of Thoracic Oncology Volume 4, Number 4, April 2009 Anatomy, Biology and Concepts TABLE 2. Stage Groups in the IASLC Staging Classification a Stage group T N M I Ia T1a,b N0 M0 Ib T2a N0 M0 II IIa T1a,b N1 M0 T2a N1 M0 T2b N0 M0 IIb T2b N1 M0 T3 N0 M0 III IIIa T1 3 N2 M0 T3 N1 M0 T4 N0,1 M0 IIIb T4 N2 M0 T1 4 N3 M0 IV T Any N Any M1a,b a Reflects the IASLC staging Committee s recommendations and not necessarily the UICC 7th edition staging system. IASLC, International Association for the Study of Lung Cancer; TNM, tumor, node, metastasis. TABLE 3. Cancer Proposed Patterns of Biologic Behavior of Lung Tumors marked by: Propensity for local growth/invasion Propensity for lymph node involvement Propensity for multifocal disease in lung parenchyma Propensity for systemic dissemination Attempting to predict biologic behavior is fraught with more uncertainty than identifying clinical patterns of presentation. It seems reasonable, however, to use characteristics observed in individual tumors at presentation to estimate the future behavior. In very early tumors, there may be insufficient growth or development to form the basis for a prediction. In tumors presenting somewhat later in their development we think that the predominant pattern observed at presentation may well predict future behavior. Anatomic descriptors remain the most studied aspects of lung cancers, and are the only characteristics for which data exists in a large number of patients. Furthermore, the proposed categorization shown in Table 4 has the advantage that it is readily applicable around the world (without genomic analysis). Therefore it seems that this might be a useful tool to investigate how well we are able to predict biologic behavior. There is ample clinical experience indicating that some tumors primarily grow and invade locally, and seem to have a diminished propensity for nodal or systemic dissemination. Many reports substantiate that patients with local invasion of additional structures exhibit good survival after resection, particularly when a complete resection is accomplished. The good outcome with local therapy alone corroborates the postulated decreased propensity for dissemination. A common example are tumors invading the chest wall (consistent 50 60% 5 years survival for T3N0M0 tumors after R0 resection). 14 Good survival has been reported after complete resection of T4 inv N0M0 tumors invading the vertebral column or carina However, much of the data is difficult to interpret because of inclusion of patients with nodal involvement and incomplete resections. In the extensive database of the IASLC staging project, the good survival of patients with locally invasive or large tumors without significant nodal involvement was clearly documented. In summary, although there may be difficulties in the ability to deliver effective local therapy to tumors marked by local invasion, there is data to support the postulated decreased propensity for nodal or systemic metastases in this subgroup. Patients with tumors involving lymph nodes seem to have a higher propensity for both regional and systemic recurrence. Treatment increasingly involves both more aggressive local therapy as well as more aggressive systemic therapy. This includes adjuvant chemotherapy after completely resected stage II(N1) and IIIa(N2) tumors, exploration of the role of surgery in addition to chemotherapy and radiotherapy in stage IIIa(N2), and the use of high dose three-dimensional conformal radiotherapy together with chemotherapy for stage III(N2,3) tumors. 22 The category that is the most obviously distinct, yet also the hardest to accurately define, are the patients with additional nodules of tumor in the lungs. It has long been recognized that a satellite focus of cancer in the same lobe carries a good prognosis, only slightly different than that of the same tumor without a satellite Similarly, multiple studies have suggested relatively good outcomes for patients with an additional focus of tumor in an ipsilateral different lobe, clearly better than for patients with other forms of distant spread. 23,25 30,32,33 Frequently such patients have multiple additional malignant foci in the lungs. 27,28,33,34 An extreme example of this process may be those patients with what is termed a pneumonic type of adenocarcinoma, meaning diffuse involvement of a portion of the lung parenchyma A mechanism for how such spread occurs is not readily apparent, but the clinical observations do not seem to fit the concepts of either lymphatic or hematogenous dissemination. It appears that a better concept for the behavior of these tumors is not spread from one area to another, but the development of multifocal disease. This may be due to field cancerization, or it may be a yet obscure change in the host microenvironment that sets the stage for this pattern of tumor development. These tumors appear to have a lower propensity for nodal involvement or distant dissemination. 29,33,37 40 Data regarding the proportions of patients entered into the IASLC database (Table 5) shows that the majority of patients fall into the category defined by the extent of nodal involvement (57%). A smaller group is characterized by the extent of the primary tumor (28%). The patients whose stage is characterized by the presence of additional nodules of tumor account for only a small proportion (2.5%). Although a population-based registry is needed to define the true Copyright 2009 by the International Association for the Study of Lung Cancer 439
4 Detterbeck et al. Journal of Thoracic Oncology Volume 4, Number 4, April 2009 TABLE 4. Stage Group IASLC Stage Grouping Aligned by Patterns of Biologic Behavior a Local Growth and Invasion Nodal Involvement Multifocal Disease (Additional Nodules) T N T N T N I a T1a,b N0 M0 I b T2a N0 M0 II a T2b > 5 N0 M0 T1a,b N1 M0 T2a N1 M0 II b T2b > 5 N1 M0 T3 b inv,> 7 N0 M0 T3 Satell N0 M0 III a T3 b inv,> 7 N1 M0 T4 inv N0,1 M0 T1 3 Any N2 M0 T3 Satell N1 M0 T4 Ipsi Nod N0,1 M0 III b T4 inv N2 M0 T1 4 Any N3 M0 T4 Ipsi Nod N2 M0 Systemic Dissemination IV M1a c Contr Nod M1a c PlDissem M1b c a Reflects the IASLC staging Committee s recommendations and not necessarily the UICC 7 th Edition Staging System. b T3 Cent is included whenever T3 inv is denoted; it is not separately recorded in order to simplify the table. c Any T, Any N. M incidence of these categories of patients, the IASLC database provides a rough estimate of the proportions. This rough estimate points out that the impression of complexity in the IASLC staging system is created primarily by relatively small subsets of patients. DISCUSSION A critical examination of accepted clinical concepts is important because so much of how we approach patients, and even how we conduct research, is driven by preconceived beliefs (often in the absence of data). Viewing the IASLC stage subgroups from the perspective of patterns of clinical presentation has several potential benefits. There is reason to think that these patterns of clinical presentation may well correlate with biologic behavior of the tumor. This categorization may have implications for the relevance of local and systemic therapies as well as of specific pretreatment staging procedures. It may turn out that a particular treatment strategy that addresses a pattern of biologic behavior may be useful for many patients within a vertical category outlined in Table 4, even though the patients fall within different stage groups. We should consider these concepts as we analyze the results of new treatments so that we do not overlook an observation because we are focused only on horizontal stage groups as a whole. What exactly is meant by biologic behavior of a tumor? From a clinical standpoint, the relevant issues are the rapidity of growth of the tumor and the pattern of spread into adjacent organs or distant sites. By definition, a cancer has the ability to grow in an unlimited fashion, to invade other normal tissues, and/or to metastasize and grow in sites distant from the primary tumor. It is the aggressiveness of the tumor and the pattern of dissemination that have the greatest influence on prognosis and on the general approach to treatment. On a cellular level, biologic behavior includes the genetic, regulatory and metabolic factors that determine cellular growth. It also includes the interactions between tumor cells, the local tissue microenvironment and the host in general. We have by necessity focused on the macroscopic aspects of tumor biology rather than cell signaling or genomic aspects. Clearly major advances are being made into understanding cellular mechanisms of tumor growth At present, however, these insights are limited to small groups of patients. More importantly, characterization of tumors by cellular biologic features requires sophisticated laboratory analysis, and thus from a practical standpoint is not easy to incorporate in clinical practice. Furthermore, cellular biologic features are not currently readily grafted onto the lung cancer staging system, which remains grounded in anatomic features. This is not meant to imply that molecular biologic 440 Copyright 2009 by the International Association for the Study of Lung Cancer
5 Journal of Thoracic Oncology Volume 4, Number 4, April 2009 Anatomy, Biology and Concepts TABLE 5. Relative Proportion of IASLC Stage Grouping by Patterns of Biologic Behavior a Stage Group I a I b TNM Classification T1a,b N0 M0 T2a N0 M0 II a T2b 5 N0 M0 4 T1a,b N1 M0 T2a N1 M0 Relative Proportion (% of all patients) b Tumor Extent Nodal Involvement Multifocal (Add l Nodules) Systemic Dissemination II b T2b 5 N1 M0 2 T3 c inv,> 7 N0 M0 13 T3 Satell N0 M0 0.6 III a T3 c inv,> 7 N1 M0 6 T4 inv N0,1 M0 2 T1 3 Any N2 M0 20 T3 Satell N1 M0 0.3 T4 Ipsi Nod N0,1 M0 0.4 III b T4 Inv N2 M0 1 d T1 4 Any N3 M0 3 e T4 Ipsi Nod N2M0 0.3 IV M1a f Contr Nod 0.9 M1a f Pl Dissem 3 M1b f 10 Total (%) a Reflects the IASLC staging Committee s recommendations and not necessarily the UICC 7 th Edition Staging System. b Proportion of patients in IASLC database as defined by best stage (pathologic, if available, otherwise clinical). 2 Values are a percentage, rounded to the nearest integer (or nearest 10th when less than 1). This incidence of patients within the IASLC database does not necessarily represent the true incidence of each stage group, because the data came from a variety of source types, and exclusion criteria may have disproportionately excluded more patients in certain subgroups (e.g. incomplete data may be more common among M1 patients). c T3 Cent is included whenever T3 inv is denoted; it is not separately recorded in order to simplify the table. d Including T4N3M0. e Excluding T4N3M0. f Any T, Any N characterization is less important; in fact it may become the dominant factor at some point in the future. It is simply less broadly applicable across the world and less readily applicable to the lung cancer stage classification system at this time. Adding biologic categorization to the anatomic grouping of the staging system may be most helpful in patients in the stage III group. These patients comprise a large percentage of patients with NSCLC and a group whose optimal care has been particularly difficult to define, perhaps because stage III includes a variety of T and N subgroups. The clinical pattern of presentation may help guide the selection of appropriate treatment. For example, an extensive surgical resection may be curative for a T4 Inv N0M0 tumor but less beneficial in patients with a T1-3N2M0 tumor. Conversely systemic treatment with a new targeted agent may be of benefit in patients with a T1-3N2M0 tumor but not for those with a T4 Inv N0M0 tumor. A limited (sublobar) resection may be of value for a T4 Ipsi Nod N0M0 tumor but not a T1N2M0 tumor. There is reason to consider a propensity for nodal involvement separately from a propensity for distant metastases. Although increasing nodal stage is clearly associated with an increased incidence of distant metastases, dissemination via the lymphatic system is no longer considered the mechanism for the development of distant metastases. Clinical experience certainly documents many patients who develop distant metastases after an apparent curative resection, but never have any evidence of nodal involvement. Multiple studies have shown that tumor cells are commonly present in the bone marrow or peripheral blood, even in patients with early stage lung cancer, when assessed by sensitive assays Moreover, the ability to detect these cells does not correlate with the nodal stage, although it is significantly associated with a higher distant recurrence rate The development of metastases is determined by a complex interplay of characteristics of the tumor cell population, the host microenvironment and the interactions between them. 50 It is best to consider a propensity for nodal involvement and for systemic metastases separately, although both factors may be at play in many patients. The proposed categorization within the IASLC stage groupings seems logical when dealing with tumors at the ex- Copyright 2009 by the International Association for the Study of Lung Cancer 441
6 Detterbeck et al. Journal of Thoracic Oncology Volume 4, Number 4, April 2009 tremes (e.g., a T1N3M0 or a T4 Inv N0M0 tumor), but it is less obvious how some other subgroups should be viewed. For example, should a T4 Inv N2M0 (stage IIIb) tumor be categorized predominantly by the invasive nature of the primary tumor or by a propensity for lymphatic involvement? In this example there may be a difference between direct extension of the primary tumor into a node versus spread to noncontiguous nodes via lymphatic channels. The same reasoning may be applicable to T2b 5 N1M0, T3 Inv N1M0 and T4 Inv N1M0 tumors: i.e., there may be a difference between direct lymph node invasion and involvement of noncontiguous nodes. Another group of patients in whom the clinical presentation does not lend itself easily to speculation about the biologic behavior are those patients with multifocal disease as well as node involvement. For T3 Satell N1M0orT4 Ipsi N1M0 tumors it is easier to accept the multifocal characteristic as being the most distinctive feature. However, patients with a T4 Ipsi N2M0 tumor may be much more likely to actually have multiple metastases, with the additional parenchymal nodule being the only distant site that was apparent at presentation. 23,24 In other words, such patients may, in fact, turn out to fit better with patients with a propensity for nodal and for systemic spread, similar to the T1-3 Any N2M0 or T Any N Any M1b patients. Reclassifying such patients in this manner, however, is in conflict with the IASLC staging committee s findings and recommendations. Furthermore, only a minority of patients with additional pulmonary foci of cancer present with N2 nodal involvement. 2,29 Therefore, it seems most appropriate to view the T4 Ipsi N2M0 patients among other patients with multifocal disease and as a subgroup of stage IIIb, consistent with the IASLC staging committee s recommendations, at least until significant data is generated that supports a different view. Whether pleural dissemination should be viewed as a form of direct invasion, of multiple nodules or of distant dissemination is also unclear. It may be that there are different types of patients with pleural involvement (e.g., those with otherwise limited disease and no effusion but with several visceral pleural nodules, and those with a malignant pleural effusion, who often have large tumors with significant nodal involvement). The fact that patients with pleural dissemination but no nodal metastases have exhibited good survival after resection (25 30% 5 year survival) corroborates this speculation. 3,51 However, most patients with pleural dissemination have extensive tumors, multiple metastases, and poor survival. Therefore, we think it is best to consider these patients as having a form of distant metastatic spread, at least until we can develop a valid way to subclassify them. Other methods of defining the biologic behavior of a lung cancer do not appear to be close to being ready for clinical application. There have been many reports that positron emission tomography (PET) intensity correlates with prognosis, suggesting that PET intensity may be a marker for the metabolic rate of a tumor as well as the propensity to metastasize. 52 However, these studies have generally not accounted for other prognostic factors such as tumor size or stage. The only carefully controlled, prospective study found that PET intensity offers no significant independent prognostic information, and that size and stage are the dominant factors. 11 Much attention has also been given to characterization of genetic changes in tumor cells. 53,54 However, most of the studies have had significant methodological flaws, and clinical application appears elusive. 55 Furthermore, different studies have identified different genes as predictive of the same outcome with only rare overlap. 56 In general, the prognostic prediction based on genetic characterization does not outperform conventional clinical and pathologic factors at this time. 12,56 The IASLC staging committee also considered this issue, and concluded that molecular characterization of tumors was insufficiently studied to be included in the current staging revision. We believe that using patterns of clinical presentation as a potential tool to predict the behavior of a tumor is a reasonable avenue to explore. Clearly research is needed to determine whether the speculation of a propensity to a particular type of progression is borne out. Because the ability to define biologically similar cohorts using anatomic characteristics will be imperfect, it is likely that the categorization proposed will not predict patterns of behavior in all subgroups. Nevertheless, we believe that the concept of incorporating patterns of biologic behavior is worthy of exploration. We hope the proposed categorization will stimulate a productive debate, and that clinical investigation may bring about deeper insights into tumor biology that prove useful in the management of patients with lung cancer. REFERENCES 1. Goldstraw P, Crowley J. The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer. J Thorac Oncol 2006;1: Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2: Rami-Porta R, Ball D, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the T descriptors in the forthcoming (7th) edition of the TNM classification of lung cancer. J Thorac Oncol 2007;2: Postmus P, Brambilla E, Chansky K, et al. The IASLC lung cancer staging project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007;2: Rusch VW, Crowley J, Giroux DJ, et al. The IASLC lung cancer staging project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2: Groome PA, Bolejack V, Crowley J, et al. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2: Detterbeck F, Tanoue L, Boffa DJ. The New Lung Cancer Staging System. Chest 2009; In press. 8. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon: stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985;312: Morgensztern D, Goodgame B, Baggstrom M, Gao F, Govindan R. The effect of FDG-PET on the stage distribution of non-small cell lung cancer. J Thorac Oncol 2008;3: Detterbeck F, Gibson C. Turning gray: the natural history of lung cancer over time. J Thorac Oncol 2008;3: Vesselle H, Freeman JD, Wiens L, et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res 2007;13: Copyright 2009 by the International Association for the Study of Lung Cancer
7 Journal of Thoracic Oncology Volume 4, Number 4, April 2009 Anatomy, Biology and Concepts 12. Sun Z, Yang P. Gene expression profiling on lung cancer outcome prediction: present clinical value and future premise. Cancer Epidemiol Biomarkers Prev 2006;15: Sculier JP, Chansky K, Crowley J, Van Meerbeeck JP, Goldstraw P. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM classification of malignant tumors and the proposals for the 7th Edition. J Thorac Oncol 2008;3: Detterbeck FC, Kiser AC. T3 non-small cell lung cancer (stage IIb-IIIa). In Detterbeck FC, Rivera MP, Socinski MA, Rosenman JG. (Eds.), Diagnosis and Treatment of Lung Cancer: an Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA: W.B. Saunders, Pp Gandhi S, Walsh GL, Komaki R, et al. A multidisciplinary surgical approach to superior sulcus tumors with vertebral invasion. Ann Thorac Surg 1999;68: Grunenwald DH, Mazel C, Girard P, et al. Radical en bloc resection for lung cancer invading the spine. J Thorac Cardiovasc Surg 2002;123: Yokomise H, Gotoh M, Okamoto T, et al. En bloc partial vertebrectomy for lung cancer invading the spine after induction chemoradiotherapy. Eur J Cardiothorac Surg 2007;31: Dartevelle P. Extended operations for the treatment of lung cancer. Ann Thorac Surg 1997;63: de Perrot M, Fadel E, Mercier O, et al. Long-term results after carinal resection for carcinoma: Does the benefit warrant the risk? J Thorac Cardiovasc Surg 2006;131: Macchiarini P, Altmayer M, Go T, et al. Technical Innovations of Carinal Resection for Nonsmall-Cell Lung Cancer. Ann Thorac Surg 2006;82: Rea F, Marulli G, Schiavon M, et al. Tracheal sleeve pneumonectomy for non small cell lung cancer (NSCLC): short and long-term results in a single institution. Lung Cancer 2008;61: Detterbeck F, Gettinger S, Socinski M. Lung Neoplasms. In Norton J, Barie P, Bollinger R, et al. (Eds.), Surgery: Basic Science and Clinical Evidence, 2nd Ed. New York: Springer, Pp Shen KR, Meyers BF, Larner JM, Jones DR. Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest 2007;132:290S 305S. 24. Detterbeck FC, Jones DR, Funkhouser Jr WK. Satellite nodules and multiple primary cancers. In Detterbeck FC, Rivera MP, Socinski MA, Rosenman JG, (Eds.), Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician. Philadelphia, PA: W.B. Saunders, Pp Okada M, Tsubota N, Yoshimura M, Miyamoto Y, Nakai R. Evaluation of TMN classification for lung carcinoma with ipsilateral intrapulmonary metastasis. Ann Thorac Surg 1999;68: Urschel JD, Urschel DM, Anderson TM, Antkowiak JG, Takita H. Prognostic implications of pulmonary satellite nodules: are the 1997 staging revisions appropriate? Lung Cancer 1998;21: Deslauriers J, Brisson J, Cartier R, et al. Carcinoma of the lung: evaluation of satellite nodules as a factor influencing prognosis after resection. J Thorac Cardiovasc Surg 1989;97: Fukuse T, Hirata T, Tanaka F, et al. Prognosis of ipsilateral intrapulmonary metastases in resected nonsmall cell lung cancer. Eur J Cardiothorac Surg 1997;12: Zell J, Ignatius Ou SH, Ziogas A, Anton-Culver H. Survival improvements for advanced stage nonbronchioloalveolar carcinoma-type nonsmall cell lung cancer cases with ipsilateral intrapulmonary nodules. Cancer 2008;112: Okumura T, Asamura H, Suzuki K, Kondo H, Tsuchiya R. Intrapulmonary metastasis of non-small cell lung cancer: a prognostic assessment. J Thorac Cardiovasc Surg 2001;122: Bryant AS, Pereira SJ, Miller DL, Cerfolio RJ. Satellite pulmonary nodule in the same lobe (T4N0) should not be staged as IIIB non-small cell lung cancer. Ann Thorac Surg 2006;82: Battafarano RJ, Meyers BF, Guthrie TJ, Cooper JD, Patterson GA. Surgical resection of multifocal non-small cell lung cancer is associated with prolonged survival. Ann Thorac Surg 2002;74: Nakata M, Sawada S, Yamashita M, et al. Surgical treatments for multiple primary adenocarcinoma of the lung. Ann Thorac Surg 2004; 78: Chang YL, Wu CT, Lee YC. Surgical treatment of synchronous multiple primary lung cancers: experience of 92 patients. J Thorac Cardiovasc Surg 2007;134: Wislez M, Massiani MA, Milleron B, et al. Clinical Characteristics of pneumonic-type adenocarcinoma of the lung. Chest 2003;123: Akira M, Atagi S, Kawahara M, et al. High-resolution CT findings of diffuse bronchioloalveolar carcinoma in 38 patients. Am J Roentgenol 1999;173: Garfield D, Cadranel J, Wislez M, Franklin WA, Hirsch F. The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases. J Thorac Oncol 2006;1: Travis WD, Garg K, Franklin WA, et al. Evolving Concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol 2005;23: McElvaney G, Miller RR, Muller NL, et al. Multicentricity of adenocarcinoma of the lung. Chest 1989;95: Trousse D, Barlesi F, Loundou A, et al. Synchronous multiple primary lung cancer: an increasing clinical occurrence requiring multidisciplinary management. J Thorac Cardiovasc Surg 2007;133: Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinicalresponse to gefitinib therapy. Science 2004;304: Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004;350: Shedden K, Taylor JMG, Enkemann SA, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14: Pantel K, Izbicki JR, Angstwurm M, et al. Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res 1993;53: Pantel K, Izbicki J, Passlick B, et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 1996;347: Ohgami A, Mitsudomi T, Sugio K, et al. Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer. Ann Thorac Surg 1997;64: Cote R, Beattie E, Chaiwun B, et al. Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Ann Surg 1995;222: Detterbeck FC, Jones DR, Molina PL. Extrathoracic staging. In Detterbeck FC, Rivera MP, Socinski MA, Rosenman JG. (Eds.), Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician. Philadelphia: W.B. Saunders, Pp Alix-Panabieres C, Riethdorf S, Pantel K. Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res 2008;14: Langley RR, Fidler IJ. Tumor Cell-Organ Microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 2007;28: Shimizu J, Oda M, Morita K, et al. Comparison of pleuropneumonectomy and limited surgery for lung cancer with pleural dissemination. J Surg Oncol 1996;61: Berghmans TD, Dusart M, Paesmans M, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and metaanalysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008;3: Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. New Engl J Med 2006;355: Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. New Engl J Med 2007;356: Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007;99: Sun Z, Wigle DA, Yang P. Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol 2008;26: Copyright 2009 by the International Association for the Study of Lung Cancer 443
The 8th Edition Lung Cancer Stage Classification
The 8th Edition Lung Cancer Stage Classification Elwyn Cabebe, M.D. Medical Oncology, Hematology, and Hospice and Palliative Care Valley Medical Oncology Consultants Director of Quality, Medical Oncology
More informationAn Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationImaging of Lung Cancer: A Review of the 8 th TNM Staging System
Imaging of Lung Cancer: A Review of the 8 th TNM Staging System Travis S Henry, MD Associate Professor of Clinical Radiology Cardiac and Pulmonary Imaging Section University of California, San Francisco
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationSeventh Edition of the Cancer Staging Manual and Stage Grouping of Lung Cancer. Quick Reference Chart and Diagrams
CHEST Special Features Seventh Edition of the Cancer Staging Manual and Stage Grouping of Lung Cancer Quick Reference Chart and Diagrams Omar Lababede, MD ; Moulay Meziane, MD ; and Thomas Rice, MD, FCCP
More informationRevisiting Stage IIIB and IV Non-small Cell Lung Cancer. Analysis of the Surveillance, Epidemiology, and End Results Data
CHEST Revisiting Stage IIIB and IV Non-small Cell Lung Cancer Analysis of the Surveillance, Epidemiology, and End Results Data William N. William, Jr, MD; Heather Y. Lin, PhD; J. Jack Lee, PhD; Scott M.
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More information8th Edition of the TNM Classification for Lung Cancer. Proposed by the IASLC
8th Edition of the TNM Classification for Lung Cancer Proposed by the IASLC Introduction Stage classification - provides consistency in nomenclature - improves understanding of anatomic extent of tumour
More information6 th Reprint Handbook Pages AJCC 7 th Edition
6 th Reprint Handbook Pages AJCC 7 th Edition AJCC 7 th Edition Errata for 6 th Reprint Table 1 Handbook No Significant Staging Clarifications for 6 th Reprint AJCC 7 th Edition Errata for 6 th Reprint
More informationStandard treatment for pulmonary metastasis of non-small
ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji
More informationLung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09
Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationLung Cancer Staging: The Revised TNM Classification
Norwegian Society of Thoracic Imaging Oslo, October 2011 Lung Cancer Staging: The Revised TNM Classification Sujal R Desai King s College Hospital, London Lung Cancer The Scale of the Problem Leading cause
More informationEvaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution
Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution Kotaro Kameyama, MD, a Mamoru Takahashi, MD, a Keiji Ohata, MD, a
More informationB REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment
B REAST STAGING FORM CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery (DCIS) (LCIS) (Paget s) mi c a b c d TUMOR SIZE:
More informationB REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment
B REAST STAGING FORM Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery (DCIS) (LCIS) (Paget s) mi a b c a b c d TUMOR SIZE: S TAGE
More informationAJCC-NCRA Education Needs Assessment Results
AJCC-NCRA Education Needs Assessment Results Donna M. Gress, RHIT, CTR Survey Tool 1 Survey Development, Delivery, Analysis THANKS to NCRA for the following work Developed survey with input from partners
More informationRole of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City
Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery
More informationAlthough ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis
Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,
More informationIn the mid 1970s, visceral pleural invasion (VPI) was included
ORIGINAL ARTICLE Tumor Invasion of Extralobar Soft Tissue Beyond the Hilar Region Does Not Affect the Prognosis of Surgically Resected Lung Cancer Patients Hajime Otsuka, MD,* Genichiro Ishii, MD, PhD,*
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationThe tumor-node-metastasis (TNM) system is
LUNG CARCINOMA STAGING PROBLEMS Philip T. Cagle, MD a,b, * KEYWORDS Lung Carcinoma Staging Tumor-node-metastasis TNM system ABSTRACT The tumor-node-metastasis (TNM) system is the most commonly used staging
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationStaging of lung cancer provides a common language
The 1997 International Staging System for Non-Small Cell Lung Cancer* Have All the Issues Been Addressed? Swan S. Leong, MD; Caio M. Rocha Lima, MD; Carol A. Sherman, MD; and Mark R. Green, MD The International
More informationThe T4 category of lung cancer is defined by invasion of the
Original Article Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category? Shun-ichi Watanabe, MD,* Hisao Asamura,
More informationGUIDELINES FOR CANCER IMAGING Lung Cancer
GUIDELINES FOR CANCER IMAGING Lung Cancer Greater Manchester and Cheshire Cancer Network Cancer Imaging Cross-Cutting Group April 2010 1 INTRODUCTION This document is intended as a ready reference for
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationVisceral pleura invasion (VPI) was adopted as a specific
ORIGINAL ARTICLE Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival Its Implications for the Forthcoming TNM Staging Based on a Large-Scale Nation-Wide Database Junji Yoshida,
More informationThe 7th Edition of TNM in Lung Cancer.
10th European Conference Perspectives in Lung Cancer. Brussels, March 2009. The 7th Edition of TNM in Lung Cancer. Peter Goldstraw, Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic
More informationPrognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer
Prognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer Jagan Rao, FRCS(C-Th), Rana A. Sayeed, FRCS(C-Th), Sandra Tomaszek, Stefan Fischer, MD, Shaf Keshavjee, MD, FRCSC, and Gail
More informationThe 8th Edition of the TNM Classification for Lung Cancer Background, Innovations and Implications for Clinical Practice
The 8th Edition of the TNM Classification for Lung Cancer Background, Innovations and Implications for Clinical Practice University of Torino Lecture 28th June 2017 Torino, Italy Ramón Rami-Porta Thoracic
More informationStage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis
Original Article Stage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis Jingxu Li, Xinguan Yang, Tingting
More informationAccepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD
Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference:
More informationCollaborative Stage. Site-Specific Instructions - LUNG
Slide 1 Collaborative Stage Site-Specific Instructions - LUNG In this presentation, we are going to review the AJCC Cancer Staging criteria for the lung primary site. Slide 2 Reading Assignments As each
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationNode-Negative Non-small Cell Lung Cancer
ORIGINAL ARTICLE Node-Negative Non-small Cell Lung Cancer Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy, RMRA, Jocelyn McLean, RN, MN, and
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationHistopathology of NSCLC, IHC markers and ptnm classification
ESMO Preceptorship on Non-Small Cell Lung Cancer November 15 th & 16 th 2017 Singapore Histopathology of NSCLC, IHC markers and ptnm classification Prof Keith M Kerr Department of Pathology, Aberdeen University
More informationThe International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project
Page 1 of 15 PRIVILEGED COMMUNICATION The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project PROCOTOL FOR PURPOSE OF GRANT APPLICATION AND ETHICS REVIEW IASLC Staging
More informationLUNG STAGING FORM LATERALITY: LEFT RIGHT BILATERAL
LUNG STAGING FORM LATERALITY: LEFT RIGHT BILATERAL ( ) Tx Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging
More informationPulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
European Journal of Cardio-Thoracic Surgery 41 (2012) 25 30 doi:10.1016/j.ejcts.2011.04.010 ORIGINAL ARTICLE Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
More informationFDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave
FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.
More informationLung cancer involving neighboring structures is classified
GENERAL THORACIC Subcategorization of Resectable Non-Small Cell Lung Cancer Involving Neighboring Structures Noriaki Sakakura, MD, Shoichi Mori, MD, Futoshi Ishiguro, MD, Takayuki Fukui, MD, Shunzo Hatooka,
More informationThe accurate assessment of lymph node involvement is
ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*
More informationDescriptor Definition Author s notes TNM descriptors Required only if applicable; select all that apply multiple foci of invasive carcinoma
S5.01 The tumour stage and stage grouping must be recorded to the extent possible, based on the AJCC Cancer Staging Manual (7 th Edition). 11 (See Tables S5.01a and S5.01b below.) Table S5.01a AJCC breast
More informationLungStage. Bringing machine learning to Nuclear Medicine and Lung Cancer using Big Data, Machine Learning and Multicenter Studies
LungStage Bringing machine learning to Nuclear Medicine and Lung Cancer using Big Data, Machine Learning and Multicenter Studies Medical Team: Bram Stieltjes, MD PhD; Alex Sauter, MD; Gregor Sommer, MD;
More informationLA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II
AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco
More informationLung 8/7/14. Collecting Cancer Data: Lung NAACCR Webinar Series. August 7, 2014
Collecting Cancer Data: Lung 2013 2014 NAACCR Webinar Series August 7, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationPrognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis
< A supplementary figure and table are published online only at http://thx.bmj.com/content/ vol65/issue3. 1 Institute of Clinical Medicine, National Yang-Ming University, 2 Department of Surgery, Cathay
More information3/23/2017. Disclosure of Relevant Financial Relationships. Pathologic Staging Updates in Lung Cancer T STAGE OUTLINE SURVIVAL ACCORDING TO SIZE ONLY
Pathologic Staging Updates in Lung Cancer Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME
More informationFDG PET/CT in Lung Cancer Read with the experts. Homer A. Macapinlac, M.D.
FDG PET/CT in Lung Cancer Read with the experts Homer A. Macapinlac, M.D. Patient with suspected lung cancer presents with left sided chest pain T3 What is the T stage of this patient? A) T2a B) T2b C)
More informationONLINE CONTINUING EDUCATION ACTIVITY
ONLINE CONTINUING EDUCATION ACTIVITY Take free quizzes online at acsjournals.com/ce ARTICLE TITLE: Lung Cancer Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual
More informationSTAGE CATEGORY DEFINITIONS
CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX Tis Tis (DCIS) Tis (LCIS) Tis (Paget s) T1 T1mi T1a T1b T1c a b c
More informationIn non small cell lung cancer, metastasis to lymph nodes, the N factor, is
Okada et al General Thoracic Surgery Border between N1 and N2 stations in lung carcinoma: Lessons from lymph node metastatic patterns of lower lobe tumors Morihito Okada, MD, PhD Toshihiko Sakamoto, MD,
More informationThe 8 th Edition of TNM for Lung Cancer: The IASLC Proposals.
13 th Cambridge Chest Meeting 2015. The 8 th Edition of TNM for Lung Cancer: The IASLC Proposals. Peter Goldstraw, Honorary Consultant Thoracic Surgeon, Royal Brompton Hospital, Emeritus Professor of Thoracic
More informationResected Synchronous Primary Malignant Lung Tumors: A Population-Based Study
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationPET CT for Staging Lung Cancer
PET CT for Staging Lung Cancer Rohit Kochhar Consultant Radiologist Disclosures Neither I nor my immediate family members have financial relationships with commercial organizations that may have a direct
More informationApplicability of the revised International Association for the Study of Lung Cancer staging system to operable non-small-cell lung cancers
European Journal of Cardio-thoracic Surgery 36 (2009) 1031 1036 www.elsevier.com/locate/ejcts Applicability of the revised International Association for the Study of Lung Cancer staging system to operable
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationSurgery for early stage NSCLC
1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what
More informationSatellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer
Satellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer Ayesha S. Bryant, MSPH, MD, Sara J. Pereira, MD, Daniel L. Miller, MD, and Robert James Cerfolio,
More informationChapter 2 Staging of Breast Cancer
Chapter 2 Staging of Breast Cancer Zeynep Ozsaran and Senem Demirci Alanyalı 2.1 Introduction Five decades ago, Denoix et al. proposed classification system (tumor node metastasis [TNM]) based on the dissemination
More informationSurgical management of lung cancer
Surgical management of lung cancer Nick Roubos FRACS Cardiothoracic Surgeon Box Hill Hospital, Epworth Eastern Thoracic Oncology Non Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer Mesothelioma Pulmonary
More informationLung cancer is one of the leading causes of death in most
ORIGINAL ARTICLE Japanese Lung Cancer Registry Study of 11,663 Surgical Cases in Demographic and Prognosis Changes Over Decade Noriyoshi Sawabata, MD, PhD,* Etsuo Miyaoka, PhD, Hisao Asamura, MD, PhD,
More informationClinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer
Original Article Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Jun Zhao*, Jiagen Li*, Ning Li, Shugeng Gao Department of Thoracic Surgery, National
More informationMEDIASTINAL STAGING surgical pro
MEDIASTINAL STAGING surgical pro Paul E. Van Schil, MD, PhD Department of Thoracic and Vascular Surgery University of Antwerp, Belgium Mediastinal staging Invasive techniques lymph node mapping cervical
More informationVisceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size
GENERAL THORACIC Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD, Neda Kalhor, MD, Wayne L. Hofstetter,
More informationLymph node dissection for lung cancer is both an old
LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko
More informationNeues von der IASLC - Proposals zur 8ten Edition der TNM Klassifikation für das Lungenkarzinom. J. Pfannschmidt
Neues von der IASLC - Proposals zur 8ten Edition der TNM Klassifikation für das Lungenkarzinom J. Pfannschmidt Immunhistochemie durchgängig zur Klassifizierung Integration der molekularen Analyse Neuklassifizierung
More informationChirurgie beim oligo-metastatischen NSCLC
24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital
More informationACRIN NLST 6654 Primary Lung Cancer. F1/F2 Interval: to (mm-dd-yyyy) 1. Date of diagnosis: (mm-dd-yyyy)
No. F1/F2 Interval: - - 20 to - - 20 (mm-dd-yyyy) 1. Date of diagnosis: - - 20 (mm-dd-yyyy) 2. Samples recorded: ZP Number S-Number 1) 2) 3) 4) (Refer to Form PX, Column 1. In the rare instance of a diagnosis
More informationThe Stage Classification of Lung Cancer
CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES The Stage Classification of Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians
More information6 th Reprint Manual Pages AJCC 7 th Edition
6 th Reprint Manual Pages AJCC 7 th Edition AJCC 7 th Edition Errata for 6 th Reprint Table 1 Manual No Significant Staging Clarifications for 6 th Reprint AJCC 7 th Edition Errata for 6 th Reprint Table
More informationSpecial Treatment Issues in Non-small Cell Lung Cancer
CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Special Treatment Issues in Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College
More informationLYMPHATIC DRAINAGE IN THE HEAD & NECK
LYMPHATIC DRAINAGE IN THE HEAD & NECK Like other parts of the body, the head and neck contains lymph nodes (commonly called glands). Which form part of the overall Lymphatic Drainage system of the body.
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationCollecting Cancer Data: Lung
Collecting Cancer Data: Lung NAACCR 2011 2012 Webinar Series 2/2/2012 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this
More informationLung /1/16. Please submit all questions concerning webinar content through the Q&A panel. Reminder:
1 NAACCR 2015-2016 Webinar Series Collecting Cancer Data: Lung NAACCR 2015 2016 Webinar Series Presented by: Angela Martin amartin@naaccr.org Jim Hofferkamp jhofferkamp@naaccr.org Q&A Please submit all
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationWHITE PAPER - SRS for Non Small Cell Lung Cancer
WHITE PAPER - SRS for Non Small Cell Lung Cancer I. Introduction This white paper will focus on non-small cell lung carcinoma with sections one though six comprising a general review of lung cancer from
More informationACOSOG Thoracic Committee. Kemp H. Kernstine, MD PhD
ACOSOG Thoracic Committee Kemp H. Kernstine, MD PhD ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy Govindan, M.D. Carolyn Reed, MD
More informationLung Cancer Clinical Guidelines: Surgery
Lung Cancer Clinical Guidelines: Surgery 1 Scope of guidelines All Trusts within Manchester Cancer are expected to follow this guideline. This guideline is relevant to: Adults (18 years and older) with
More informationEVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced
More informationExtent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Mesothelioma
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Mesothelioma [Based on WOSCAN SCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED WHEN PRINTED Document
More informationImpact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer
Impact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer Jakob R. Izbicki, MD, Bernward Passlick, MD, Ortrud Karg, MD, Christian Bloechle, MD, Klaus Pantel, MD, Wolfram
More informationMultifocal Lung Cancer
Multifocal Lung Cancer P. De Leyn, MD, PhD Department of Thoracic Surgery University Hospitals Leuven Belgium LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery Department of Pneumology Department
More informationVisceral pleural invasion (VPI) of lung cancer has been
ORIGINAL ARTICLE Visceral Pleural Invasion Classification in Non Small- Cell Lung Cancer in the 7th Edition of the Tumor, Node, Metastasis Classification for Lung Cancer: Validation Analysis Based on a
More informationAccording to the current International Union
Treatment of Stage II Non-small Cell Lung Cancer* Walter J. Scott, MD, FCCP; John Howington, MD, FCCP; and Benjamin Movsas, MD Based on clinical assessment alone, patients with stage II non-small cell
More informationRESEARCH COMMUNICATION. Occult Micrometastasis to Bone Marrow in Early Lung Cancer: A Clinicopathologic Study from West Bengal, India
RESEARCH COMMUNICATION Occult Micrometastasis to Bone Marrow in Early Lung Cancer: A Clinicopathologic Study from West Bengal, India Saumitra Biswas 1*, Supriya Sarkar 2, Jayati Chakraborty 1, Sudipta
More informationSurgical resection is the first treatment of choice for
Predictors of Lymph Node and Intrapulmonary Metastasis in Clinical Stage IA Non Small Cell Lung Carcinoma Kenji Suzuki, MD, Kanji Nagai, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, and Yutaka Nishiwaki,
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationSleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib
Case Report Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib Ichiro Sakanoue 1, Hiroshi Hamakawa 1, Reiko Kaji 2, Yukihiro Imai 3, Nobuyuki Katakami 2, Yutaka Takahashi 1 1 Department
More informationTherapeutic value of lymph node dissection for right middle lobe non-small-cell lung cancer
Original Article Therapeutic value of lymph node dissection for right middle lobe non-small-cell lung cancer Hiroaki Kuroda 1,2, Yukinori Sakao 1,2, Mingyon Mun 2, Noriko Motoi 3, Yuichi Ishikawa 3, Ken
More informationNAACCR Webinar Series 1
Collecting Cancer Data: Lung 2013 2014 NAACCR Webinar Series August 7, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationCODING STAGE: TNM AND OTHER STAGING SYSTEMS. Liesbet Van Eycken Otto Visser
CODING STAGE: TNM AND OTHER STAGING SYSTEMS Liesbet Van Eycken Otto Visser OVERVIEW PART I Introduction What is stage? Why stage? History and publications of TNM Classification Clinical and pathologic
More informationStaging for Residents, Nurses, and Multidisciplinary Health Care Team
Staging for Residents, Nurses, and Multidisciplinary Health Care Team Donna M. Gress, RHIT, CTR Validating science. Improving patient care. Learning Objectives Introduce the concept and history of stage
More information